A lack of synergy between membrane-permeabilizing cationic antimicrobial peptides and conventional antibiotics  by He, Jing et al.
Biochimica et Biophysica Acta 1848 (2015) 8–15
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamemA lack of synergy between membrane-permeabilizing cationic
antimicrobial peptides and conventional antibioticsJing He, Charles G. Starr, William C. Wimley ⁎
Department of Biochemistry and Molecular Biology, Tulane University School of Medicine, New Orleans, LA 70112, USA⁎ Corresponding author. Tel.: +1 504 988 7076.
E-mail address: wwimley@tulane.edu (W.C. Wimley).
http://dx.doi.org/10.1016/j.bbamem.2014.09.010
0005-2736/© 2014 Elsevier B.V. All rights reserved.a b s t r a c ta r t i c l e i n f oArticle history:
Received 14 May 2014
Received in revised form 16 September 2014
Accepted 20 September 2014
Available online 28 September 2014
Keywords:
Antimicrobial peptide
Synergy
Antagonism
CheckerboardThe rapid rise inmorbidity andmortality fromdrug-resistant pathogenic bacteria has generated elevated interest
in combination therapy using antimicrobial agents. Antimicrobial peptides (AMPs) are a candidate drug class to
advance the development of combination therapies. Although the literature is ambiguous, the genericmembrane
disrupting activity of AMPs could enable them to synergize with conventional small molecule antibiotics by
increasing access to the cell and by triggering membrane damage mediators. We used a novel assay to measure
interactions, expressed as fractional inhibitory concentration (FIC), between four conventional antibiotics in
combination with four well-characterized, membrane permeabilizing AMPs, against three species of Gram
negative and Gram positive bacteria, giving 40 total pair-wisemeasurements of FIC with statistical uncertainties.
We chose a set of AMPs that are known to dramatically disrupt themembranes of both Gram negative and Gram
positive bacteria. Yet none of the membrane permeabilizing antimicrobial peptides interacted synergistically
with any of the conventional antibiotic drugs in any organism. Large-scale membrane disruption and
permeabilization by AMPs is not sufﬁcient to drive them to act synergistically with chemical antibiotics in either
Gram negative or Gram positive microbes.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
One of the most signiﬁcant and widespread problems in infectious
disease treatment is the development of resistance to chemotherapeu-
tics. Alarmingly, drug-resistant and multidrug-resistant bacteria, such
as methicillin resistant Staphylococcus aureus (MRSA) or vancomycin
resistant Enterococcus faecalis, have become commonplace in hospitals,
leading to very signiﬁcant morbidity and mortality from previously
treatable bacterial infections [1]. The rise of community acquired drug
resistant infections has caused additional concern and has led some to
question whether we have reached “the end of antibiotics”[2].
Because of the ineffectiveness of current antibiotic treatment
options for drug-resistant bacterial infections, alternate classes of anti-
biotics are desperately needed and combination therapies must be
seriously considered as a routine approach to antibacterial chemother-
apy. Cationic antimicrobial peptides (AMP) that target the microbial
membrane directly have long been a promising treatment alternative
[3–8] for direct use, or for use in combination with other antibiotics.
Yet, their potential is still mostly unfulﬁlled. The potential advantages
of membrane permeabilizing antimicrobial peptides are signiﬁcant.
They have broad-spectrum μM activity against many strains of Gram
negative and Gram positive bacteria, in vitro, including drug-resistant
strains [4,7,9–20]. Furthermore, resistance to AMPs is uncommon andis not readily selectable or inducible [21,22], unlike the case for most
chemical antibiotics. This is likely due to the fact that AMPs act on bac-
terial membranes globally, and not with a particular macromolecular
component of the cell. The need to alter the architecture of the entire
membrane to achieve resistance likely increases the overall ﬁtness cost.
Multidrug combinations are sometimes used for the treatment of
routine bacterial infections [23,24] as well as tuberculosis [25]. Thus it
is reasonable to propose a combination therapy utilizing AMPs and
chemical antibiotics because the mechanism of action of membrane
permeabilizing antimicrobial peptides is so dramatically different from
the chemical antibiotics. It has been proposed in the literature that
AMPs could synergize with antibiotics increasing the permeability of
bacterial membranes [26], including the outer membrane of Gram
negative bacteria. It has also been suggested that AMPs could enhance
the activity of bacterial murein hydrolases [27,28] or other enzymes
that decrease the integrity of the peptidoglycan layer, allowing antibi-
otics that affect cell wall synthesis (e.g. β-lactams) to act more efﬁcient-
ly. However, the data in the literature are ambiguous with some
AMP–drug combinations reported to have synergy and some reported
to not have synergy.
To measure antimicrobial synergy, one measures minimum inhibi-
tory concentration (MIC) for growth in a broth dilution experiment.
This is often done in a “checkerboard” type assay in which compounds
A and B are serially diluted in the rows and columns of a multiwell
plate, respectively, and the wells with no growth at the intersection
between the effective concentrations of A and B are noted [29]. While
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have noted signiﬁcant weaknesses in this approach [29–33], mainly
arising from the fact that only one or a few wells in an entire plate
actually provide information on synergy. This lack of statistical
robustness causes the results to be sensitive to random experimental
error. It also means that seemingly trivial differences in the method
of interpreting checkerboard results can lead to very different
conclusions, even for the same raw data [30,31], an observation
that we conﬁrm below. These issues could explain why the literature
on AMP–antibiotic synergy is ambiguous. For this work, we have
developed a more robust synergy assay that circumvents many of
the problems associated with checkerboard assays. This novel assay
provides sensitive and statistically robust measurements of drug
interactions with low sensitivity to random or systematic, day-to-
day experimental error.
We use this novel assay to make an extensive set of statistically
robust FIC measurements on all pairwise combinations of four well-
characterized, membrane permeabilizing cationic antimicrobial pep-
tides (AMP) and four classes of traditional chemical antibiotics against
three species of bacteria, including both Gram positive and Gram nega-
tive species. In total, we measured 40 individual pairwise interactions.
No statistically signiﬁcant evidence for synergy or antagonism was
detected in any combination; all pairs showed either simple additivity
or independence of effects, suggesting that substantial membrane
disruption caused by AMPs does not automatically lead to synergy,
and does not fully explain the synergistic interactions observed for
some peptide–drug pairs.
2. Materials and methods
2.1. Materials
Peptides were synthesized and puriﬁed by Biosynthesis, Inc. Puri-
ty and identity were independently veriﬁed by HPLC and MALDI
mass spectrometry. The sequences of the peptide are as follows:
*VAYR* = RRGWVLALYLRYGRR; *ARVA = RRGWLALRLVLAY; and
VVRG = WVLVLRLGY. Antibiotics were purchased from Sigma-
Aldrich. Bacteria were obtained from ATCC and cultured/propagated
according to the standard protocols.
2.2. Measurement of MIC
Bacteria were grown to a log phase culture and then diluted to
4 × 105 in tryptic soy broth (TSB). Cells were added to each well of
a plate containing serially diluted peptide, antibiotic or both. In ad-
dition, the plates were incubated overnight at 37 °C. Optical
density measurements the next day showed a binary response,
with almost all wells either opaque (OD600 ≥ 0.6) or transparent
(OD600 ≤ 0.08). The rare wells with partial growth were considered
to be not inhibited.
2.3. Fractional inhibitory concentration
FIC in a drug mixture is deﬁned as
FICAB ¼
MICComboA
MICAloneA
þMIC
Combo
B
MICAloneB
where MICs are measured for pure compounds and in mixtures of the
two. FIC is not necessarily expected to be constant for all ratios of
compounds A and B, however when the concentration ratio is similar
to the MIC ratio, FIC values are relatively insensitive to small changes
in the ratio between A and B. This is the regimewhere the experiments
reported here are done.2.4. Measurement of FIC
To the top row of a sterile 96-well platewe added 3 ×MIC of peptide
in four columns, 3 × MIC of antibiotic in four columns, and 1.5 × MIC
of each peptide and antibiotic mixed, in four columns. Then
the top row was serially diluted row by row by a factor of 2/3.
4 × 105 bacterial cells/mL (as above) were added to each well and
the plates were incubated overnight at 37 °C. Optical density measure-
ments the next day showed a binary response, with almost all wells
either opaque (OD600 ≥ 0.6) or transparent (OD600 ≤ 0.08). Rare wells
with partial growth or single microbial colonies were considered to be
not inhibited.
2.5. Statistical analyses
The number of consecutive inhibitedwells, starting from the highest
concentration, rather than the actual drug concentration, was the raw
data used in statistical calculations because well numbers are normally
(Gaussian) distributed, while the concentrations calculated from them
are not. For each set of experiments, we tabulated the number of unam-
biguously inhibited wells for peptide, for antibiotic and for the mixture.
These valueswere entered into the programSynerStat, which calculates
average dilution number (and standard deviation) for each column of
peptide, antibiotic and mixture. (The analysis software is freely avail-
able from the authors upon request). FIC was calculated using a non-
parametric, brute force numerical averaging of all the possible data
combinations, giving a Gaussian-distributed mean FIC, SD and SE. Test-
ing for rejection of potential outliers was done using Chauvenet's crite-
rion, but essentially no data points were rejected. The correct N is the
equivalent number of unique experiments performed. In these experi-
ments, there are 4 experiments for each 96 well plate. In all cases we
used at least four plates (N ≥ 16).
3. Results and discussion
3.1. Antimicrobial peptides, antibiotics and microorganisms
To test the hypothesis that membrane disruption will lead to syner-
gistic interactions with chemical antibiotics, we use three well charac-
terized peptides that were selected in a high-throughput screen for
synthetic bilayer permeabilization [34]. These cationic, interfacially
active [35] peptides, referred to as *VAYR*, *ARVA and VVRG are
15, 12 and 9 residues long, respectively (see sequences above) with
charges of +6, +4 and +2. They all bind selectively and strongly to
microbes with partial β-sheet secondary structure and permeabilize
their cytoplasmic membranes [15,16]. However some of the details of
their actions vary. For example *VAYR* causes very rapid cytoplasmic
membrane depolarization of Escherichia coli (~20 s). It also causes
rapid entry of membrane impermeant SYTOX Green DNA binding dye
into Gram positive and Gram negative bacteria within about 10 min.
SYTOX Green is larger and more polar than most antibiotics [15] and
thus is a good surrogate marker for antibiotic entry into cells. On the
other hand, *ARVA does not cause membrane depolarization over the
ﬁrst 3 min, but by 5 min allows SYTOX Green into all bacteria tested.
Interestingly VVRG is broadly microbicidal and causes large scale
permeabilization of S. aureus membranes to SYTOX Green, but does
not have the same effect in E. colimembranes. Despite the differences
in apparent molecular mechanism, the peptide MIC values (which actu-
ally areminimum sterilizing concentrations) are all similar in the low μM
range. These AMPs have activity against all Grampositive andGramneg-
ativemicrobes thatwe have tested, including drug resistant strains. They
also have sterilizing activity against the pathogenic fungi Cryptococcus
neoformans and Candida albicans [16,34]. Furthermore, these peptides
have low cytolysis and cytotoxicity against mammalian cells [15].
The fourth peptide we tested was melittin, which belongs to a very
different class. Melittin is a generic membrane permeabilizing (i.e. lytic)
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Fig. 1. Checkerboard synergy assays. A: A simulated checkerboard synergy assay for anti-
biotic interactions. Both hypothetical compounds are diluted serially from 8 × MIC by a
factor of 2 each step. Shown is a single result from a simulation to which a small random
experimental error was added. Colorless wells are inhibited. Gray wells are not inhibited.
Yellow wells mark the last inhibited wells at the boundary. The numbers in the wells are
the minimum FIC values that would be required for inhibition of that well. The red
borderedwell is the single lowest FIC observed for an inhibitedwell. B: An actual checker-
board assaywhichwas performed twice. *ARVA and streptomycinwere serially diluted by
two-fold from 15 μM each and used to inhibit S. aureus. The color coding is the same as
above except that green wells were inhibited in only one of two repeats.
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eukaryotic and fungal membranes indiscriminately [36]. Melittin is not a
candidate AMP drug because it is highly toxic to human cells as well as
bacteria. We use it here to assess whether a potently lytic class of
membrane permeabilizing peptide can act synergistically with chemical
antibiotics.
The chemical antibiotics tested were as follows: ampicillin
(a β-lactam that inhibits cell wall synthesis), ciproﬂoxacin (a ﬂuoro-
quinolone that inhibits DNA gyrase), streptomycin (an aminoglycoside
that inhibits protein synthesis), and vancomycin (a glycopeptide that
inhibits cell wall synthesis in Grampositivemicrobes). The site of action
of ampicillin and vancomycin is outside of the cytoplasmic membrane,
while ciproﬂoxacin and streptomycin act intracellularly. We used
three strains of bacteria: E. coli (ATCC 25922) and Pseudomonas
aeruginosa (ATCC 27853) as representative Gram negative organisms,
and S. aureus (ATCC 25923) as a representative Gram positive microbe.
3.2. Weaknesses of the checkerboard assay
Mechanistic interactions between antibiotics are usually measured
with some version of the broth dilution “checkerboard” assay. While
this type of assay is convenient to perform, itsweaknesses and statistical
ambiguity have been well described in the literature [29–33]. As an
example, a simulated checkerboard antibiotic interaction assay is
shown in Fig. 1A. Hypothetical compound A is diluted by serial 2-fold
steps horizontally and compound B is diluted in 2-fold steps vertically.
Clear wells indicate the absence of growth (i.e. inhibition), while gray
wells indicate growth. Yellow wells mark the last inhibited wells at
the boundary between inhibition and growth. The numbers in the
wells are the minimum FIC values that would be required to inhibit
the microbe in that particular well in the array. The well bordered in
red has the lowest FIC of any inhibited well. If there was no experimental
variance, and if the drugs acted in an ideally additive manner (FIC = 1),
the red box would delineate the area that would not be inhibited. The
blue box indicates wells that would not be inhibited if the drugs acted
completely independently (FIC = 2). In this simulated experiment, FIC
has been set to 0.5, moderately synergistic, and a small, realistic amount
of random experimental variation has been added
In this workwe use the simple mathematical deﬁnition of FIC b 1 for
synergy, 1 ≤ FIC ≤ 2 for additivity to independence and FIC N 2 for an-
tagonism. However we note that many authors follow more conserva-
tive guidelines and use the following values: Synergy: FIC ≤ 0.5;
Additivity: 0.5 b FIC ≤ 2; Indifference: 2 b FIC ≤ 4; Antagonism
FIC N 4. In the experiments in Fig. 1A, if there is a synergy between the
drugs (FIC b 1) then additional wells inside the red boxwill be inhibited.
The FIC values of the last inhibited wells at the interface between inhi-
bition and no inhibition carry the information used to calculate FIC.
However, this highlights one of the weaknesses of the checkerboard
assay because there are at least four ways to interpret such an experi-
mental result, as shown by White and colleagues [30,32,33]. These
various approaches to determining FIC from a checkerboard assay give
very different answers with respect to synergy, even when applied to
the same raw data [30–33]. While the true FIC value lies between the
last inhibited and ﬁrst non-inhibited well, the boundary values vary
signiﬁcantly at the interface because the “slope” of the FIC change per
row/column varies throughout the plate matrix. In the example
shown in Fig. 1A, towhichwe have added a small random experimental
variance, the boundary FIC values range from 1.1 to 0.4. To analyze a
checkerboard assay result, one can average all of the FIC values at the
boundary (although there are several different ways to identify bound-
ary wells [30]) which will provide what might seem like a statistically
robust number, but one that will be far from a true random sampling
of a parent population and thus does not actually have any statistical
meaning. The average FIC will always be an overestimate of the true
FIC. Alternately, researchers sometimes note the single well with
the smallest FIC value that was inhibited. This approach will give astatistically weak number that is highly sensitive to experimental
error (with N=1 for an entire 96-well plate), but one that may be clos-
er to the true value. Finally, FIC values from checkerboard assays can be
signiﬁcantly affected by small systematic errors in theMIC valueswhich
are used to calculate FIC.While some authors measureMIC on the same
plate as the checkerboard, reducing systematic errors due to day-to-day
variations, others rely on previous MIC measurements to calculate FIC.
Given the exponential nature of serial dilutions, small variations in
MIC can lead to large systematic errors in FIC.
The weaknesses of the checkerboard assay are further exempliﬁed
by the actual checkerboard assay data shown in Fig. 1B. In this case,
we performed two independent checkerboard assays with an antimi-
crobial peptide and a chemical antibiotic against S. aureus under nomi-
nally identical conditions. Colorless wells in Fig. 1B were inhibited in
both plates, green wells were inhibited in only 1 of the 2 plates, and
gray wells were not inhibited in either plate. Notice here again, the
11J. He et al. / Biochimica et Biophysica Acta 1848 (2015) 8–15boundary wells (in yellow/green) range widely from FIC= 2.0 to 0.3. If
we average the common boundary wells observed in both plates we
obtain a minimum FIC of 1.2 +/− 0.4, indicating simple additivity. But
these are not really independent measurements, thus the uncertainty
has little physical meaning. If we average the set of boundary wells
with the lowest FIC observed in either plate, then the minimum
FIC = 0.8 +/− 0.5. If we average the lowest FIC single wells observed
in each plate (red bordered wells in Fig. 1B), we get FIC= 0.45, indicat-
ing synergy. But, since the SD is undeﬁned in this case, we do not know
the error in FIC value without analyzing additional individual plates.
Thus, as discussed above [30–33], the very same data can have widely
different interpretations in checkerboard assays (FIC for this one data
set ranges from 1.2 to 0.45) and there is no universal consensus on
how such assays should be interpreted. (Note: Using the new assay
described here, we obtain FIC = 1.5 +/− 0.2 (SD, N = 16) for this
pair of compounds against S. aureus, see below).
3.3. A robust assay for antibiotic interactions
The assay we developed for this work was designed for increased
statistical power in a multiwell plate-based measurement of FIC,
and for circumventing the weaknesses of the checkerboard assay.Melittin    + + + + - - - - + + + +
Ampicillin  - - - - + + + + + + + +
AMP x 2/3 serial dilution
MIC
Rows: 4 3 4 2|2 2 2 2|2 2 2 
A
Example
Fig. 2. Example assay plates from the novel antibiotic interaction assaywe developed here. Top:
2/3 fold serial dilution of melittin from 15 μM. Colorless wells have no growth (and no detecta
calculated by averaging the number of wells sterilized and then converting themean to concent
S. aureus. The ﬁrst two sets of columns contain either peptide or antibiotic diluted by 2/3 serial
diluted by 2/3 from 1.5 ×MIC for each. Clear wells have no growth after overnight incubation. O
done using the number of consecutive wells that were inhibited from the highest concentratioTo perform the assay, ﬁrst the MIC of the two compounds is measured
independently, as in Fig. 2A. While these MIC determinations are used
to design the assay plates, they are not used to calculate FIC. Next,
96-well assay plates are designed with three sets of four columns,
where each set of columns contains compound A only, compound B
only, or a mixture of compounds A and B. Compounds A and B are
serially diluted from 3 × MIC down by a factor of 2/3. As such, the
third row of each column has each compound present above the ex-
pected MIC (1.3 × MIC) and the fourth row is below the expected
MIC (0.9 × MIC). In the absence of day-to-day experimental variance,
the third rowwill be the last inhibited row for the pure compounds. Nor-
mal experimental variance for 2/3 serial dilution can be up to +/− 1
row, especially for peptides (see Fig. 2). If the compounds are ideally ad-
ditive, (FIC = 1) the third row of mixture will also be the last inhibited
row. If there is synergy, the mixture will inhibit more rows than the
pure compounds. An average of one additional row will be inhibited
for FIC = 0.67, two additional rows will be inhibited for FIC = 0.44 and
three additional rows will be inhibited for FIC = 0.3. If there is antago-
nism, the mixture will inhibit fewer rows than the pure compounds.
Example plates for this assay are shown in Fig. 2. After overnight incuba-
tion, inhibited wells have no growth and have low optical density.
Non-inhibited wells have stationary phase growth and high optical+ + + + - - - - + + + +
- - - - + + + + + + + +
xMICA xMICB
xMICB
xMICA
2 3 2 4 3|2 1 2 2|2 2 2 2
 Data Collecon
SimpleMICmeasurement for a peptide antibiotic against S. aureus. Each row is a repeat of a
ble CFUs). Opaque wells have stationary phase growth after overnight incubation. MIC is
ration. Bottom: Two interaction assay plates for the peptidemelittin and ampicillin against
ly from 3 ×MIC. The third set of four columns contains a mixture of peptide and antibiotic
paque wells have stationary phase growth after overnight incubation. All calculations are
n.
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ﬁcation of inhibited wells is straightforward.
By comparing pure compounds and mixtures side by side, this
assay design eliminates the effect of errors or day-to-day ﬂuctuation
in MIC. In a typical MIC assay, there are many sources of variation
that can lead to random or systematic errors in inhibition by at
least one row in a 2/3 serial dilution assay. In a checkerboard assay,
uncertainties or ﬂuctuation in MIC can dominate the measurement
of drug interaction because they directly enter into the calculation
of FIC. In the new assay, the effect of systematic experimental errors
is greatly reduced because we obtain FIC values directly using multi-
ple side-by-side measurements of MIC using pure compounds and
mixtures. Neither errors in the a priori knowledge of MIC, nor sys-
tematic errors in the measurement of MIC affect the determination
of FIC in our assay.
We note here that the conditions where FIC is most sensitive to
interactions is when both compounds are present in a ratio that is
equal to the ratio of their MIC values. One potential disadvantage of
this assay compared to the checkerboard assay is that the latter
simultaneously explores multiple ratios of the two compounds
being tested. However, large variations in synergy at ratios that are
far from the ratio of pure MICs are extremely rare. To more accurate-
ly measure the MIC and FIC, we use small serial dilutions of 2/3.
Finally, each plate contains four measurements of each compound's
MIC and four measurements of the mixture's MIC. Thus four
measurements of FIC are made on each plate by directly comparing
mixtures with individual compounds on the same plate.Rows Sterilized in Figure 2A:
Peptide:    (Pi) 4,3,4,2,3Antibiotic: (Aj)      2,2,2,2,2Combination:(Ck)      2,2,2,2,2
kk
ji
Combo Combo
C C
ijk Alone Alone
P A
MIC MIC
FIC
MIC MIC
Example Data Anal
Fig. 3. Example data analysis for determining FIC. Top: Each column in a plate (see Fig. 2) provid
bination columns, a single FIC can be calculated from the number ofwells inhibited. The overall F
a bootstrap approach that is based on the calculation of FIC for all possible combinations of exp
ample plates in Fig. 2. In this example, the peptide ismelittin (m) and the antibiotic is ampicillin.
calculate all possible individual FIC values using thenumber of rows inhibited. From the list of all
calculations, the effective N is the number of columns assayed for each compound.3.4. Statistical analysis
Another potentially signiﬁcant source of error in synergy assays
(actually in all serial dilution assays) arises from the fact that the inhib-
itory concentration values obtained in repeats of serial dilution experi-
ments do not have a Gaussian probability distribution, and thus are
not subject to Gaussian-based statistical analyses (Student's t-tests,
standard ANOVA etc.). Non-parametric analyses are required to analyze
non-Gaussian data except at large N when the distribution of means
approaches a Gaussian distribution. The statistical calculations that we
perform here (e.g. MIC calculation) are done using the number of
consecutive wells inhibited as the raw numerical data, (instead of the
antibiotic concentration). The former do have normal (Gaussian) prob-
ability distribution (p-value for the Kolmogorov–Smirnov test for
normality N 0.1). Each 96-well synergy plate (Fig. 2) provides four
measurements, each, of the number of wells inhibited for compounds
A and B and for the mixture. While repeat measurements on one plate
are not necessarily expected to be statistically independent, we found
by ANOVA that variations in calculated FIC values within plates are
indistinguishable from the variation between plates measured on sepa-
rate days, so they are effectively independent measurements. Each FIC
measurement presented here is done using at least four plates total,
prepared over at least two separate days from new stocks.
We use a numerical (non-parametric) bootstrap averaging of all
possible FIC values using the individual values of wells inhibited from
all experimental plates combined. This is shown in Fig. 3. For calculation
of p-values, the effective sample number, N, is 4 for each plate. Given the,2,4,3
,1,2,2
,2,2,2
, ,
ijk
i j k
overall
FIC
FIC
i j k
8 MIC measurements:
A - Melin (pepde) alone
B - Ampicillin (anbioc)  alone
A+B - Mixture of both
512 possible FIC calculaons
Bootstrap Average: 
FIC  1.3 0.09 (SE, N=8)
ysis
es a single uniqueMICmeasurement. For any combination of peptide, antibiotic and com-
IC average and standard deviation from a related set of assay plates can be calculated using
erimental values. Middle: The table of values (number of rows sterilized) for the two ex-
Bottom: The program SynerStat (freely available from the authors upon request) is used to
possible FIC values, theoverall average FIC is calculated alongwith SDandSE. For statistical
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Fig. 4.Measured fractional inhibitory concentrations (FIC) for all of the combinations of
peptide, antibiotic and microbe studied in this work. In each case, at least four plates
were analyzed giving a minimum N = 16. Error bars are standard deviations calculated
from the raw data. Horizontal lines on the plates indicate mathematically ideal indepen-
dence (FIC = 2) and additivity (FIC = 1). Each panel shows data for a single drug, with
vancomycin added to the third panel. Colors indicate different organisms and the
markings above the points indicate the peptide: 15: the 15-residue peptide *VAYR*; 12:
the 12-residue peptide *ARVA; 9: the 9-residue peptide VVRG; m: the 26 residue bee
venom peptide melittin.
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provides data at N = 16 from which we can obtain statistically robust
measurements of FIC, standard deviation and standard error of the
mean for each combination.
3.5. Lack of synergy betweenmembrane permeabilizing AMPs and chemical
antibiotics
Using the new assay, we measured the FIC and standard deviations
for 40 peptide–drug–microbe combinations available from the list
above. In Table 1, we show the MIC values for each compound, alone.
The peptideMICs are all in the low μMrange. AntibioticMICs aremostly
in the low μMrangewith a fewexceptions. Ciproﬂoxacin has submicro-
molarMIC values. Ampicillin, on the other hand, has low activity against
the strain of Pseudomonas we used, requiring mM concentrations for
inhibition. Vancomycin is not active against Gram negative microbes.
The 40 interactions are expressed as FIC values +/− SD in Fig. 4B
and C. For each combination, at least four plates were analyzed, giving
at least 16 independentmeasurements of the individual MIC, combined
MIC and FIC. The results in Fig. 4 show that therewas no detectable syn-
ergy between any pair. While a fewmeasurements are below themath-
ematical cutoff of 1 for synergy, the statistical concept of multiple
parallel comparisons indicates that this is likely a Type I error and not
a statistically signiﬁcant effect. A few measurements are above the
mathematical cutoff of 2 for independence, suggesting antagonism,
but again the differences are not statistically signiﬁcant in the context
of 40 comparisons.
3.6. Comparison to published results
There aremixed reports in the literature of synergy between various
AMPs and conventional antibiotics [26,28,37–44]. The aggregated re-
sults of some representative large studies are given in Table 2. Synergy,
deﬁned bymost authors as FIC b 0.5, is reported in roughly 1 in 5 exper-
iments against Gram positive bacteria (mostly S. aureus) and in roughly
1 in 3 experiments against Gram negative bacteria (mostly E. coli and
P. aeruginosa). Many of the reported synergistic FIC values are between
0.3 and 0.5, slightly lower than the common threshold, thus statistical
uncertainties are critical for assessment of the effects. Yet, most synergy
studies, including the studies in Table 2, are striking in their complete
lack of stated statistical uncertainties. Taken together, the lack of statis-
tical uncertainties, and the large errors in FIC that can arise from small
experimental errors (see above), means that most published FIC mea-
surements for AMP/antibiotic interactions have unknown conﬁdence
intervals and unknown statistical signiﬁcance. Further adding to the
ambiguity, the large number of multiple comparisons in most synergy
studies signiﬁcantly increases the probability of type I statistical errors
(i.e. false positives), an effect that can be accounted for, as we have
done here, only if experimental uncertainties are known quantitatively.
To enable a direct comparison between published values obtained
with checkerboard assays and values obtained using the assay describedTable 1
Minimum sterilization concentration (MIC, in μM) of tested antibiotics and antimicrobial
peptides against bacteria.
E. coli S. aureus P. aeruginosa
Ampicillin 18.3 ± 2.0 14.8 ± 2.7 1.4 ± 0.3a
Ciproﬂoxacin 0.05 ± 0.01 1.8 ± 0.2 1.0 ± 0.2
Streptomycin 3.2 ± 1.8 8.9 ± 1.9 8.9 ± 1.8
Vancomycin N/Ab 86.8 ± 8.0 N/Ab
Melittin (26 aa) 2.7 ± 0.6 1.5 ± 0.4 2.3 ± 0.5
*VAYR* (15 aa) 4.3 ± 2.2 5.8 ± 1.3 7.6 ± 1.5
*ARVA (12 aa) 3.9 ± 1.3 4.1 ± 0.8 7.8 ± 3.2
VVRG (9 aa) 2.9 ± 1.6 4.8 ± 0.8 7.2 ± 1.4
a MIC of Ampicillin vs. P. aeruginosa is shown in mM.
b Gram negative strains were not susceptible to Vancomycin. In all cases uncertainties
are standard deviations and N = 16.here, we examined the literature for a peptide/antibiotic combination
that was consistently reported to display synergy. In three papers pub-
lished at nearly the same time by one laboratory, it was reported that
the amphibian AMPmagainin II interacted synergisticallywith all tested
β-lactam antibiotics [26,28,42], but not with other antibiotics. Magainin
II has a mechanism of action that may be similar to melittin but with
greater selectivity for anionic microbial membranes [45]. However un-
like melittin, which we showed here does not act synergistically with
chemical antibiotics, magaininwas reported to have FIC values between
0.15 and 0.3 for interaction with about 10 different β-lactams in multi-
ple strains of 5 different species of Gram positive and Gram negative
bacteria. Strengthening the validity of the reported synergy between
magainin and β-lactam interactions, in the same papers, synergy was
not observed between magainin II and other classes of antibiotics.
Table 2
Representative synergy results from the literature. The number of bacterial species (sp) and strains (st) is shown, alongwith the number of combinations that are synergistic over the total
tested, where synergy is deﬁned empirically by most authors as FIC b 0.5.
Study # of AMPs # of antibiotics # Gram + sp(st) FIC b 0.5 # Gram− sp(st) FIC b 0.5
This study, 2014 4 4 1 0/24 2 0/16
Niu, 2013 [37] 1 9 2 2/15 1 1/6
Yenugu,2010 [38] 2 10 – – 1 20/20
Sánchez,2010 [39] 3 12 – – 1 63/81
van der Linden,2009 [40] 2 2 1 1/4 1 0/4
Ulvatne 2001 [41] 6 8 1 1/40 1 9/40
Giacometti 2000a [42] 5 8 1(6) 48/240 2(6) 30/150
Giacometti 2000b [28] 5 8 – – 1(3) 15/120
Giacometti 2000c [26] 3 10 – – 1(2) 30/60
Zhang,1999 [43] 9 2 – – 2(4) 26/72
Scott, 1999 [44] 20 4 – – 1 16/61
14 J. He et al. / Biochimica et Biophysica Acta 1848 (2015) 8–15Nor was synergy observed between other AMPs, including the bovine
neutrophil AMP indolicidin, and β-lactam antibiotics.
Tomake this direct comparison, we used the assay described here to
measure the synergy between the peptides magainin II and indolicidin
in the presence of either of two β-lactam antibiotics, ampicillin and cef-
tazidime. The results are shown in Fig. 5, wherewe compare average FIC
values of our peptides with the four new measurements. Qualitatively,
these measurements agree well with the published results. Magainin
II interacts synergistically with both β-lactam antibiotics, relative to
the mathematical cutoff of FIC = 1 for synergy (p b 0.0001). In the
magainin II assay plates (as in Fig. 2), the combination columns showed
sterilization in one or two additional rows, compared to the pure com-
pounds. Indolicidin, like the other peptideswe studiedhere, does not in-
teract synergistically with β-lactam antibiotics (p N 0.05). By ANOVA,
both of the magainin II-antibiotic FIC values are signiﬁcantly different
from the FICs of the peptides measured here, against ampicillin, and
from the FICs for indolicidin against the two β-lactams (p N 0.001). At
the same time, indolicidin's two FIC values are not distinguishable
from the average of the peptide–antibiotic combinations described
here (p N 0.05).
3.7. Mechanistic interpretation
In this work we tested the hypothesis that membrane disruption
will lead to generic synergistic interactions between cationic antimicro-
bial peptides and chemical antibiotics. The literature is ambiguous with
respect to addressing this hypothesis and the lack of statistical robust-
ness in most of the literature makes interpretation difﬁcult. To address
this hypothesis, we developed a novel assay for antibiotic interaction
that provides an unambiguous and statistically robust measurement of0.5
1.0
1.5
2.0
Amp    Ceft
+
Indolicidin
Amp    Ceft
+
Magainin II
 F
IC
AMPs (this work)
+
All        Amp
0.0
Fig. 5. Comparison of fractional inhibitory concentrations (FIC) against E. coli. The two
points derived from this work are an average +/− SE (N= 40) for all FIC measurements
in Fig. 4, or an average +/− SE (N = 12) for all FIC using the β-lactam ampicillin. The
magainin II and indolicidin points are FIC values +/− SE (N = 16) for the combination
of peptide and the β-lactams, ampicillin or ceftazidime. FICs were measured as described
above. The lines at FIC = 1 and 2 represent the mathematical boundaries for synergy and
antagonism, respectively.FIC for drug pairs in a relatively small number of microwell plates. Fur-
thermore, we selected four antimicrobial peptides that are very well
characterized with respect to bacterial membrane disruption, including
knowledge of time-course and effective “pore size” [15,16,34,46,47].
Our results show that bacterial membrane disruption by itself does
not automatically give rise to synergy with any class of chemical antibi-
otic, including those that act intracellularly. The once example of syner-
gy we observed here, which others have also observed, between
magainin II and β-lactam antibiotics is unusual, suggesting a unique
mechanism that, for the moment, remains unknown.
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